Literature DB >> 15047774

Effect of antisense oligodeoxynucleotides for ICAM-1 on renal ischaemia-reperfusion injury in the anaesthetised rat.

Lik Voon Kiew1, Abdul Sattar Munavvar, Chung Hiong Law, Abdullah Nor Azizan, Abdul Rahman Nazarina, Khalifah Sidik, Edward J Johns.   

Abstract

An antisense oligodeoxynucleotide (As-ODN) to the 3' untranslated region of the mRNA sequence expressing the intracellular adhesion molecule-1 (ICAM-1) was employed to determine ICAM-1's role in renal ischaemia-reperfusion injury in the rat. Wistar-Kyoto rats receiving i.v. either lipofectin-As-ODN (As-ODN group), lipofectin-reverse ODN (Rv-ODN group) or lipofectin (ischaemia control group) 8 h prior to study were anaesthetized and subjected to 30 min of renal artery occlusion. Renal haemodynamic and excretory parameters were monitored before and after renal ischaemia. On termination of the study renal tissue was subjected to histological and Western blot analysis. Renal blood flow decreased in the 3 h post-ischaemia period in the ischaemia control and Rv-ODN groups, but was maintained in the As-ODN group. Glomerular filtration rate was depressed initially but gradually increased to 10% above basal levels in the ischaemia control and Rv-ODN groups, but was below basal levels (20%) in the As-ODN group. There was a three- to fourfold increase in sodium and water excretion following ischaemia in the ischaemia control and reverse-ODN groups but not in the As-ODN treated group. The As-ODN ameliorated the histological evidence of ischaemic damage and reduced ICAM-1 protein levels to a greater extent in the medulla than cortex. These observations suggested that in the post-ischaemic period afferent and efferent arteriolar tone was increased with a loss of reabsorptive capacity which was in part due to ICAM-1. The possibility arises that the action of ICAM-1 at vascular and tubular sites in the deeper regions of the kidney contributes to the ischaemia-reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047774      PMCID: PMC1665139          DOI: 10.1113/jphysiol.2004.061788

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  13 in total

Review 1.  Biology of acute renal failure: therapeutic implications.

Authors: 
Journal:  Kidney Int       Date:  1997-10       Impact factor: 10.612

2.  ICAM-1 expression and leukocyte accumulation in inner stripe of outer medulla in early phase of ischemic compared to HgCl2-induced ARF.

Authors:  Kathleen E De Greef; Dirk K Ysebaert; Veerle Persy; Sven R Vercauteren; Marc E De Broe
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

3.  Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms.

Authors:  M Y Chiang; H Chan; M A Zounes; S M Freier; W F Lima; C F Bennett
Journal:  J Biol Chem       Date:  1991-09-25       Impact factor: 5.157

4.  Mechanisms of ischemic acute renal failure.

Authors:  J V Bonventre
Journal:  Kidney Int       Date:  1993-05       Impact factor: 10.612

Review 5.  Macrophages in acute glomerular inflammation.

Authors:  V Cattell
Journal:  Kidney Int       Date:  1994-04       Impact factor: 10.612

6.  Acute renal failure in the patient undergoing cardiac operation. Prevalence, mortality rate, and main risk factors.

Authors:  G Zanardo; P Michielon; A Paccagnella; P Rosi; M Caló; V Salandin; A Da Ros; F Michieletto; G Simini
Journal:  J Thorac Cardiovasc Surg       Date:  1994-06       Impact factor: 5.209

7.  Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat.

Authors:  H Haller; D Dragun; A Miethke; J K Park; A Weis; A Lippoldt; V Gross; F C Luft
Journal:  Kidney Int       Date:  1996-08       Impact factor: 10.612

Review 8.  Renal ischaemia--reperfusion injury.

Authors:  S C Weight; P R Bell; M L Nicholson
Journal:  Br J Surg       Date:  1996-02       Impact factor: 6.939

Review 9.  Ischemic acute renal failure.

Authors:  S R Hays
Journal:  Am J Med Sci       Date:  1992-08       Impact factor: 2.378

10.  Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury.

Authors:  K J Kelly; W W Williams; R B Colvin; J V Bonventre
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

View more
  6 in total

1.  Toll-like receptor 4 regulates early endothelial activation during ischemic acute kidney injury.

Authors:  Jianlin Chen; Reji John; James A Richardson; John M Shelton; Xin J Zhou; Yanxia Wang; Qing Qing Wu; John R Hartono; Pamela D Winterberg; Christopher Y Lu
Journal:  Kidney Int       Date:  2010-10-06       Impact factor: 10.612

2.  Sticky wickets in lower nephron nephrosis.

Authors:  Friedrich C Luft
Journal:  J Physiol       Date:  2004-04-08       Impact factor: 5.182

3.  Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1.

Authors:  Qing Qing Wu; Yanxia Wang; Martin Senitko; Colin Meyer; W Christian Wigley; Deborah A Ferguson; Eric Grossman; Jianlin Chen; Xin J Zhou; John Hartono; Pamela Winterberg; Bo Chen; Anapam Agarwal; Christopher Y Lu
Journal:  Am J Physiol Renal Physiol       Date:  2011-02-02

Review 4.  Acute kidney injury: a conspiracy of Toll-like receptor 4 on endothelia, leukocytes, and tubules.

Authors:  Christopher Y Lu; Pamela D Winterberg; Jianlin Chen; John R Hartono
Journal:  Pediatr Nephrol       Date:  2011-10-28       Impact factor: 3.714

5.  Endothelial pentraxin 3 contributes to murine ischemic acute kidney injury.

Authors:  Jianlin Chen; Martin M Matzuk; Xin J Zhou; Christopher Y Lu
Journal:  Kidney Int       Date:  2012-08-15       Impact factor: 10.612

6.  Hydrogen Sulphide Treatment Prevents Renal Ischemia-Reperfusion Injury by Inhibiting the Expression of ICAM-1 and NF-kB Concentration in Normotensive and Hypertensive Rats.

Authors:  Syed F Hashmi; Hassaan Anwer Rathore; Munavvar A Sattar; Edward J Johns; Chee-Yuen Gan; Tan Yong Chia; Ashfaq Ahmad
Journal:  Biomolecules       Date:  2021-10-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.